[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pten\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pten":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100615786","pten-and-organ-specific-micrornas-in-metastatic-breast-cancer-100615786",false,"NCT07297134","PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer","Serum PTEN Levels and Organ-Specific microRNA Signatures as Predictors of Metastatic Patterns in Breast Cancer: A Prospective Observational Study","PTEN-miR-MBC","Inclusion Criteria:\n\n* Female individuals aged ≥18 years\n* Ability to provide written informed consent\n* Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically proven distant organ metastasis at the time of enrollment\n* Group II (Non-Metastatic BC): Histopathologically confirmed breast cancer with no evidence of distant metastasis\n* Group III (Healthy Controls): Women ≥18 years with no known breast disease and no personal history of malignancy\n\nExclusion Criteria:\n\n* History of any other primary malignancy\n* Known breast disease or breast cancer diagnosis in Group III\n* Immunosuppressive therapy that may alter immune or biomarker profiles\n* Active infection or inflammatory condition that may alter biomarker levels\n* Inability or unwillingness to provide informed consent\n* Severe hepatic, renal, or hematologic dysfunction\n* Current pregnancy or lactation",true,"FEMALE","18 Years",{"count":21,"type":22},160,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40).\n\nThe primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.",[26,27,28,29],"Breast Cancer","Metastatic Breast Cancer","miRNAs","PTEN",[26,27,28,29,31,32,33],"Breast Cancer Biomarkers","Organ Specific Metastasis","miRNA Profiling","RECRUITING","2026-01-26",{"date":37,"type":38},"2026-01-27","ACTUAL",{"date":40,"type":38},"2025-12-01",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"Atlas University","OTHER"]